NitroMed thins out R&D
NitroMed eliminates roughly 30 research and development positions effective March 31. The restructuring is a cost-cutting measure in line with an "increased focus on sales and marketing," the firm says. The move comes just a week after the exit of the company's CEO and CFO as the firm struggles with sluggish sales of its niche heart failure drug BiDil (1"The Pink Sheet" March 27, 2006, p. 14). NitroMed officials say the firm will continue to focus on other nitric-oxide enhancing drugs, including an extended-release formulation of BiDil (isosorbide/hydralazine)...
You may also be interested in...
NitroMed's strategy for jump-starting sales of BiDil includes renewed efforts to get favorable formulary placement for the heart failure drug
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.